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Purpose: To report the use of non-invasive multi-spectral imaging of a female choroideremia (CHM)
carrier with mild visual symptoms and extensive fundus mottling.
Observation: This was an observational case report study. A symptomatic 42-year-old female with a
history of binocular CHM presented for routine ocular examination and underwent review of her clinical
and photographic records, optical coherence tomography (OCT), intravenous ﬂuorescein angiography
(IVFA) and multi-spectral imaging (MSI). Dilated fundus examination and photography revealed similar
outcomes of diffuse mottling with normal looking vessels. IVFA showed large irregular and conﬂuent
patches of RPE atrophy in the peripapillary and parapapillary areas as well as the midperiphery, corre-
sponding to the OCT ﬁndings. The entire range of MSI imaging (520e940 nm) clearly illustrated the
anomalies of the fundus including retinal pigment epithelium (RPE) mottling with melanin clumping not
readily seen with the other imaging modalities. MSI fundus autoﬂuorescence (MSI-FAF) showed a spotty
hypo and hyperautoﬂuorescent appearance of the fundus, consistent with the observations seen on IVFA
and OCT images.
Conclusion and Importance: MSI signiﬁcantly improves visualization of the retinal pigment epithelium in
choroideremia. The non-invasive nature of MSI technique is a valuable tool in monitoring the effect of
retinal and choroidal presentation in patients with CHM.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Choroideremia (CHM) is a recessive X-linked chorioretinal
dystrophy caused by mutation in the CHM Xq21 gene which en-
codes the protein REP-1 [1]. The condition is a progressive, diffuse
degeneration of the choroid, retina, retinal pigment epithelium
(RPE) and photoreceptors. Symptoms include bilateral nyctolopia in
childhood followed by annular scotomas leading to concentric vi-
sual ﬁeld loss and impairment of visual acuity, color vision and
stereopsis by mid-adulthood, speciﬁcally in males. Fundus changes
are observed as non-speciﬁc pigmentary stippling and focal areas of
choroidal atrophy in the mid-periphery. With degenerative
changes of the RPE, window defects showing remnants of the
choroidal vasculature become apparent in peripapillary areas andaple Grove Road, Ottawa, ON
).
Inc. This is an open access article umacula. As the disease advances, the sclera becomes visible on
fundus examination in the areas of complete choroidal and retinal
atrophy.
Differential diagnosis includes retinitis pigmentosa and gyrate
atrophy. In the former there is a greater amount of pigment
migration and in the later there is elevated plasma concentration of
orinithine. Non-invasive visualization of the RPE can assist in the
differential diagnosis.
Female carriers of CHM may also show varying degrees of
chorioretinopathy, RPE atrophy and granular pigmentary atrophy
in the periphery. Severe visual impairment rarely occurs and is
typically attributed to skewed X-inactivation [2]. Visual function
remains fairly good, with either no symptoms or mild to moderate
nyctalopia. Full-ﬁeld electroretinograms (ERG) vary in female car-
riers and there is no deﬁnitive expected outcome. Most cases are
normal or only slightly reduced [3].
Theories on the pathophysiology of CHM include degeneration
of rod photoreceptors followed by degeneration of the choroid or
primary RPE degeneration [2,4,5]. Advances in ocular imaging havender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. 50 fundus images of the patient showing discoloration of the retina central and
mid-peripherally (right eye < left eye).
Fig. 2. Intravenous ﬂuorescein angiography (IVFA).
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coherence tomography (OCT) is used to detect chorocapillaris loss
and choroidal neovascularization associated with CHM [6]. An
important diagnostic criterion in female carriers is the mottled RPE
changes which cause patchy fundus autoﬂuorescence (FAF) irreg-
ularities with areas of hypo and hyperautoﬂuorescence [7].
In this case report, a female carrier of CHM was imaged with
traditional technologies as well as with multi-spectral imaging
(MSI). MSI has the capability of highlighting the detailed structure
of RPE, particularly melanin for early morphologic changes that are
not generally visible clinically or with traditional fundus imaging
modalities in routine practice [8]. Given the important role of the
RPE in the pathogenesis of CHM and other retinal pathologies,
examination of this layer with MSI may prove highly valuable for
noninvasive differential diagnosis from RP and for monitoring
progression.Fig. 3. Optical coherence tomography (OCT) scans of patients eyes. The blue arrows indicate
thickness scan corresponding to hypo-reﬂective spots in the per-macular area (see green li2. Case report
A 42-year old female presented to the retinal clinic for her
annual eye examination, as directed by her physician. She was a
known carrier of choroideremia having been diagnosed in her
teens and had a positive family history of CHM, with a brother
exhibiting the disease. Best-corrected visual acuities (BCVA) were
20/20 in each eye with a refraction of þ3.00e0.50  090 OD
and þ2.50e0.75  115 OS. The patient had full confrontational
visual ﬁelds in each eye and refused to have an automated visual
ﬁeld test. Her past medical history was unremarkable with no
history of smoking. Her family history of systemic and ocular
conditions included heart diseases, arthritis, glaucoma and cata-
racts. The patient was not on any medications and was allergic to
Codeine and Omeprazole. She complained of blurry vision at dis-
tance initially, due to under-corrected refractive error, but had no
symptoms of CHM including nyctalopia. She refused an electro-
retinogram (ERG) or speciﬁc genetic testing for further assessment
of her condition.
Her ocular anterior segment examination was unremarkable.
Dilated fundus examination revealed diffuse mottling with normal
vasculature. There was some peripapillary atrophy OU. Fundus
photography images (Canon CF-1 OIS version 11.4.0) revealed
diffuse mottling and scattered changes in fundus coloration cen-
trally and in the mid-periphery (Fig. 1). The intravenous ﬂuores-
cein angiography (IVFA) images showed large irregular and
conﬂuent patches of RPE atrophy (Fig. 2). The patient was further
imaged with the spectral domain optical coherence tomography
(SD-OCT; Spectralis, Heidelberg Engineering, Germany) where
shortening of the photoreceptor inner and outer segments in areas
corresponding to RPE atrophy were observed. Additionally,
changes in the RPE thickness were seen corresponding to the
hypo-reﬂective regions on the scanning laser ophthalmoscope
(SLO) scans. The remaining laminations, however, appeared to be
normal in both eyes (Fig. 3).
The patient was imaged on the FDA approved, RHA™ Multi-
Spectral Imaging Device (Annidis Corporation, Ottawa, Canada).
The system uses twelve speciﬁc individual, non-overlapping, nar-
row-band LED light sources in a range from 520 nm to 940 nm to
create en-face spectral images throughout the posterior segment
from internal limiting membrane (ILM) to the choroid. The short-
wavelength images (MSI-580 nm and MSI-590 nm), which in-
crease the visibility of the anterior retinal layers, showed healthy
looking vasculature OU but hyper-reﬂective white anomalies were
seen in themid-periphery of both eyes (Fig. 4A and B). With the use
of longer-wavelength images (MSI-620 nm e MSI-850 nm)areas of irregularities of the retinal pigment epithelium in both eyes in the OCT en-face
nes through the area of irregularity).
Fig. 4. Multi-spectral imaging (MSI) imaging - MSI-580 (A) and MSI-590 (B) images of
the patient's eyes showing a healthy looking vasculature in both eyes and some
scattered hyper-reﬂective deposits superiorly in the left eye. MSI-620 (C), MSI-660 (D)
images of the eyes showing increased visibility of the pigment mottling and retinal
pigment epithelium disruption with an increase in wavelength and depth penetration.
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were possible and the images showed hypo-reﬂective areas as well
as deﬁned melanin pigment clumps, not seen with the other mo-
dalities and likely associated with the loss of the inner segment/
outer segment junction. (Fig. 4C and D).
The retinal oxy/deoxy maps (MSI-OH1) are the combination of
the 580 nm and 590 nm wavelength images used to enhance the
differential contrast of the retinal vasculature based on hemoglobin
oxygenation level in the vessels and the retina. Arteries appear
bright while deoxygenated veins appear dark. These images
strongly resemble IVFAwith respect to pooling of ﬂuid but are non-
invasive to obtain. The black spots seen in this case are melanin
clumps obscuring the view of the underlying choroidal structure.
They correlate directly with the spots observed with the long
wavelength MSI images (Fig. 5). The oxy/deoxy feature plays a
signiﬁcant role in the detection of vascular disorders such as early
diabetic and hypertensive retinopathies. It may help with the dif-
ferential diagnosis of CHM from RP where vessel attenuation is
generally observed.
MSI-FAF is generated by an absorption and reemission process
in which the retina is illuminated with an average wavelength of
600 nm and re-emitted at a wavelength greater than 660 nm. For
this patient, the MSI-FAF showed a primarily hypoautoﬂuorescent
fundus with some actively degenerating hyperautoﬂuorescent
areas (Fig. 6A). Such appearance is typically described as irregular
mosaic of low to high density FAF. Mottled irregularities were seen
on both sides of the vessel arcades. Multiple small ﬂecks of reduced
and single ﬂecks of increased autoﬂuorescence were also visible.
The MSI-940 images (clinical research only) of this patient are
shown in Fig. 6B. The RHA™ can capture transmission images of the
choroid by projecting 940 nm light to the back of the eye by way of
the sclera, which acts as a wave guide. Backscatter provides a high-
resolution image of the choroidal vasculature without the use of
invasive dyes. The MSI-940 images, which resemble indocyanine
green angiography (ICGA), also revealed melanin stacking in the
area of RPE disruption.
3. Discussion
Choroideremia is a progressive, recessive X-linked disease that
primarily affects males. Although, female carriers are often
asymptomatic, the fundus may show the presence of pigmentary
mottling. These clinical signs rarely lead to the visual dysfunction
and fundus manifestations experienced by males.
Although functional tests such as ERG have shown abnormal
retinal function in CHM patients [9], ERG can still be normal in the
early stages of the disease. Rod amplitude responses have been
found to be generally reduced in affected males with minimally
prolonged rod implicit times while cone amplitudes are initially
normal or reduced [10]. In female carriers, ERG amplitudes have
been found to be abnormal in only 15% of cases [9] and therefore
must be used in combination with other diagnostic techniques. In
a report on a case of CHM carrier with unilateral central vision
loss, multifocal ERG (mfERG) showed severely reduced amplitudes
associated with a band of retinal pigment epithelial and choroidal
atrophy in the macula [11]. Reports on visual ﬁeld results in car-
riers of CHM have mainly suggested normal outcomes with pos-
sibility of blind spot enlargement in some cases in an older study
[12]. This corresponds to the peripapillary atrophy seen in this
case. Grover S et al. [13] reported normal visual ﬁeld results in 6
CHM carriers who had fundus abnormalities. Another study
showed a dense central scotoma on Humphrey visual ﬁelds testing
in a case of a CHM carrier with severe unilateral central vision loss
[11]. In our case, the patient refused additional procedures
including ERG, visual ﬁelds and genetic testing for furtherassessment of her condition as it was diagnosed over 20 years
previously. MSI with FAF and a thorough clariﬁcation of family
history are readily available primary care tools to assist in the
diagnosis of the CHM state in carriers.
Using MSI, clinical signs such as peripapillary atrophy, RPE
mottling in the macular region, RPE melanin clumping, ﬂecks of
atrophy in the periphery and hypoautoﬂuorescence in areas of RPE
atrophywith somemottled hyper and hypoautoﬂuorescence can be
found in CHM carriers [7,14]. Mottled irregularities seen in FAF
imaging are helpful in identifying female CHM carriers and a
Fig. 6. Multi-spectral imaging (MSI) fundus autoﬂuorescence (MSI-FAF) (A) and MSI-
940 (B) [clinical research application only] for right and left eyes.
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OCT studies in female CHM carriers have demonstrated only subtle
RPE irregularities with attenuation more prominent outside the
macular region [15].
To the best of our knowledge, this is the ﬁrst report of a fundus
appearance of CHM carrier usingMSI. Details of this technique have
been described and published previously [16]. Conventional fundus
imaging provides minimal diagnostic value because of the poor
view of the RPE. Fundus images are useful in the documentation of
certain features, but identiﬁcation of pathologies at early stages is
limited due to color over-saturation and the impact of media
opacities such as cataracts. This limitation is even more evident
with deeper structures of the retina. With the use of MSI and the
speciﬁc selection of spectral bands, the sub-retinal structures and
metabolic features of the retina and choroid can be visualized in
ﬁner details. This makes MSI a valuable tool for diagnosing and
monitoring the effect of retinal and choroidal preservation of pa-
tients with CHM in combination with en-face high-resolution OCT.
The unique location of the RPE, between the photoreceptors and
choroid, makes it a vital feature in mediating the transport of nu-
trients and oxygen to photoreceptors. A progressive accumulation
of oxidative stress, that is an imbalance between the production of
reactive oxygen species (free radicals) and antioxidant defenses
due to pathological factors, is a fundamental mechanism involved
in RPE cell death. Previous research has shown that photoreceptor
degeneration in both humans and animal models of hereditary
retinal degenerative disease corresponds with a progressive
reduction of the retinal circulation [17,18]. To-date no known
studies have shown alteration of retinal and choroidal oxygenation
in a case of choroideremia. Loss of the choriocapillaris and the RPE
are suggested to contribute to photoreceptor degeneration in
choroideremia and the RPE is suggested as one primary site of
degeneration in patients with choroideremia [4,5]. The MSI-OH1
represents oxy/deoxyhemoglobin contrast maps which can hence
identify any disturbance in the retinal circulation and oxygenation
due to atrophy or hypoxia. MSI technology allows clinician to detect
the extent of RPE and photoreceptor abruptions in pathologies that
involve the retinal inner layer and the choroid, including CHM and
age related macular degeneration.
Clinical diagnosis of CHM can be conﬁrmedwith an immunoblot
assay. An examination of the genomic DNA or the mRNA must be
performed to identify the molecular cause of CHM. CHM carriers
with no detectable fundus signs can be identiﬁed only through such
molecular analysis [19]. The patient proﬁled here presented with a
positive family history and extensive fundusmottling. With regards
to treatment options for CHMpatients, gene therapy can potentially
improve rod and cone function and ultimately overcome any
negative effects of retinal detachment [20]. Non-invasive MSI im-
aging of the retina and choroid can be very beneﬁcial in clinicalFig. 5. Multi-spectral imaging (MSI-OH1) retinal oxy-deoxy contrast images.practice both for diagnosis and monitoring of vision threatening
pathologies including CHM. The discrete LEDs and ﬁlters used in
MSI signiﬁcantly improve visualization of vital fundus structures,
particularly the RPE. Considering the important role of the RPE and
choroid in the pathogenesis of retinal pathologies, examination of
these layers with MSI may prove highly valuable at every stage of
disease in combination with other imaging modalities.References
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